Reaction
Dental Operation reporting signals
As of the last recalculation, Dental Operation appears in 2,412 FAERS reports alongside 30 co-occurring drug terms. The strongest observed disproportionality signal is UPADACITINIB (PRR 15.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Upadacitinib | 139 | 15.6 | 15.6 |
| Calcium, Magnesium, Potassium, And Sodium Oxybates | 14 | 14.1 | 14.1 |
| Denosumab | 273 | 13.0 | 13.0 |
| Infliximab-Dyyb | 39 | 11.7 | 11.7 |
| Risankizumab-Rzaa | 105 | 11.5 | 11.6 |
| Ibrutinib | 94 | 10.4 | 10.4 |
| Chlorhexidine Gluconate | 10 | 9.5 | 9.5 |
| Zoledronic Acid | 38 | 8.3 | 8.3 |
| Sodium Oxybate | 53 | 7.1 | 7.1 |
| Naltrexone | 25 | 7.1 | 7.1 |
| Amoxicillin | 59 | 6.8 | 6.8 |
| Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, And Amphetamine Sulfate | 25 | 6.2 | 6.2 |
| Belimumab | 21 | 5.8 | 5.8 |
| Dextroamphetamine Sulfate, Dextroamphetamine Saccharate, Amphetamine Sulfate And Amphetamine Aspartate | 25 | 5.2 | 5.2 |
| Niraparib | 13 | 5.1 | 5.1 |
| Naltrexone Hydrochloride And Bupropion Hydrochloride | 5 | 5.1 | 5.1 |
| Armodafinil | 11 | 4.5 | 4.5 |
| Avapritinib | 6 | 4.3 | 4.3 |
| Emicizumab | 6 | 4.2 | 4.2 |
| Nintedanib | 14 | 3.9 | 3.9 |
| Romosozumab-Aqqg | 6 | 3.8 | 3.8 |
| Vilazodone Hydrochloride | 4 | 3.7 | 3.7 |
| Sarilumab | 11 | 3.6 | 3.6 |
| Ivacaftor | 3 | 3.3 | 3.3 |
| Tofacitinib | 63 | 3.0 | 3.0 |
| Mometasone Furoate And Formoterol Fumarate Dihydrate | 5 | 2.8 | 2.8 |
| Voxelotor | 6 | 2.3 | 2.3 |
| Oxymorphone Hydrochloride | 3 | 2.2 | 2.2 |
| Relugolix | 6 | 2.2 | 2.2 |
| Esketamine Hydrochloride | 4 | 1.9 | 1.9 |